26.60
price up icon1.18%   0.31
after-market After Hours: 26.76 0.16 +0.60%
loading
Royalty Pharma Plc stock is traded at $26.60, with a volume of 1.81M. It is up +1.18% in the last 24 hours and down -1.30% over the past month. Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$26.29
Open:
$26.345
24h Volume:
1.81M
Relative Volume:
0.80
Market Cap:
$11.79B
Revenue:
$2.24B
Net Income/Loss:
$673.24M
P/E Ratio:
236.44
EPS:
0.1125
Net Cash Flow:
$2.67B
1W Performance:
+1.45%
1M Performance:
-1.30%
6M Performance:
-0.08%
1Y Performance:
-1.99%
1-Day Range:
Value
$26.23
$26.64
1-Week Range:
Value
$26.02
$26.83
52-Week Range:
Value
$25.10
$31.66

Royalty Pharma Plc Stock (RPRX) Company Profile

Name
Name
Royalty Pharma Plc
Name
Phone
(212) 883-0200
Name
Address
110 EAST 59TH STREET, NEW YORK, NY
Name
Employee
89
Name
Twitter
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
RPRX's Discussions on Twitter

Compare RPRX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
RPRX
Royalty Pharma Plc
26.60 11.79B 2.24B 673.24M 2.67B 0.1125
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
464.56 119.70B 10.63B -479.80M -1.35B 13.33
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
754.87 82.75B 13.85B 4.65B 3.32B 35.06
Biotechnology icon
ARGX
Argen X Se Adr
614.59 36.73B 1.86B -40.29M -1.28B -4.16
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
253.74 32.53B 2.09B -332.26M 16.06M -4.14
Biotechnology icon
BNTX
Biontech Se Adr
120.72 28.50B 3.30B -501.07M 1.03B 11.54

Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-03-24 Downgrade UBS Buy → Neutral
Jun-14-22 Resumed UBS Buy
May-13-22 Initiated Scotiabank Sector Outperform
Apr-27-22 Initiated Goldman Buy
Apr-14-22 Upgrade JP Morgan Neutral → Overweight
Apr-06-22 Resumed Morgan Stanley Overweight
Oct-29-21 Upgrade Citigroup Neutral → Buy
Jul-30-21 Initiated Tigress Financial Buy
Nov-09-20 Upgrade UBS Neutral → Buy
Jul-14-20 Initiated Evercore ISI In-line
Jul-13-20 Initiated BofA Securities Buy
Jul-13-20 Initiated Citigroup Neutral
Jul-13-20 Initiated Cowen Outperform
Jul-13-20 Initiated Goldman Neutral
Jul-13-20 Initiated JP Morgan Neutral
Jul-13-20 Initiated Morgan Stanley Equal-Weight
Jul-13-20 Initiated SunTrust Buy
Jul-13-20 Initiated UBS Neutral
View All

Royalty Pharma Plc Stock (RPRX) Latest News

pulisher
Nov 27, 2024

Royalty Pharma to Present at Upcoming Investor Conferences - The Manila Times

Nov 27, 2024
pulisher
Nov 27, 2024

Royalty Pharma to Present at Two Major Healthcare Investor Conferences in December | RPRX Stock News - StockTitan

Nov 27, 2024
pulisher
Nov 27, 2024

Why Royalty Pharma (RPRX) is the Cheapest Stock to Buy on Robinhood? - Insider Monkey

Nov 27, 2024
pulisher
Nov 27, 2024

Dai ichi Life Insurance Company Ltd Has $4.79 Million Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Nov 27, 2024
pulisher
Nov 27, 2024

Qsemble Capital Management LP Buys New Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Nov 27, 2024
pulisher
Nov 26, 2024

10 Cheapest Stocks to Buy On Robinhood - Insider Monkey

Nov 26, 2024
pulisher
Nov 25, 2024

(RPRX) Trading Advice - Stock Traders Daily

Nov 25, 2024
pulisher
Nov 23, 2024

BNP PARIBAS ASSET MANAGEMENT Holding S.A. Raises Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Nov 23, 2024
pulisher
Nov 23, 2024

Royalty Pharma plc (NASDAQ:RPRX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Nov 23, 2024
pulisher
Nov 22, 2024

Thrivent Financial for Lutherans Purchases 168,905 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Nov 22, 2024
pulisher
Nov 21, 2024

Overbrook Management Corp Sells 59,504 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Nov 21, 2024
pulisher
Nov 19, 2024

Royalty Pharma (NASDAQ:RPRX) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat

Nov 19, 2024
pulisher
Nov 19, 2024

Royalty Pharma plc (NASDAQ:RPRX) Shares Acquired by Victory Capital Management Inc. - MarketBeat

Nov 19, 2024
pulisher
Nov 19, 2024

RPRXRoyalty Pharma plc Latest Stock News & Market Updates - StockTitan

Nov 19, 2024
pulisher
Nov 17, 2024

Amalgamated Bank Sells 48,057 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Nov 17, 2024
pulisher
Nov 16, 2024

Undercovered Dozen: Aurora Cannabis, FREYR Battery, Royalty Pharma, Talos Energy + - Seeking Alpha

Nov 16, 2024
pulisher
Nov 15, 2024

Royalty Pharma stock hits 52-week low at $25.2 amid market shifts - Investing.com India

Nov 15, 2024
pulisher
Nov 15, 2024

Royalty Pharma (NASDAQ:RPRX) Sets New 52-Week LowTime to Sell? - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Royalty Pharma plc (NASDAQ:RPRX) Shares Bought by Simplify Asset Management Inc. - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Royalty Pharma Announces Inaugural Prize for Impact in Healthcare - The Manila Times

Nov 15, 2024
pulisher
Nov 14, 2024

(RPRX) Technical Data - Stock Traders Daily

Nov 14, 2024
pulisher
Nov 14, 2024

Royalty Pharma Awards Inaugural Healthcare Prize to Michael Milken for Cancer Research Impact | RPRX Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 14, 2024

3 High-Yield Dividend Stocks You Can Buy With $130 Now and Hold at Least a Decade - The Motley Fool

Nov 14, 2024
pulisher
Nov 13, 2024

Ex-Dividend Reminder: Cencora, Royalty Pharma and Brookline Bancorp - Nasdaq

Nov 13, 2024
pulisher
Nov 13, 2024

Solid Earnings May Not Tell The Whole Story For Royalty Pharma (NASDAQ:RPRX) - Simply Wall St

Nov 13, 2024
pulisher
Nov 13, 2024

Royalty Pharma's (NASDAQ:RPRX) Profits May Not Reveal Underlying Issues - Yahoo Finance

Nov 13, 2024
pulisher
Nov 13, 2024

Syndax shares slide despite pivotal trial success - The Pharma Letter

Nov 13, 2024
pulisher
Nov 12, 2024

New South Capital Management Inc. Has $69.77 Million Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Baillie Gifford & Co. - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

Los Angeles Capital Management LLC Lowers Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Nov 12, 2024
pulisher
Nov 11, 2024

Van ECK Associates Corp Boosts Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Nov 11, 2024
pulisher
Nov 10, 2024

Royalty Pharma Q3 2024 Earnings Preview - MSN

Nov 10, 2024
pulisher
Nov 10, 2024

Summit Global Investments Purchases New Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat

Nov 10, 2024
pulisher
Nov 09, 2024

Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Executive Wealth Management LLC - MarketBeat

Nov 09, 2024
pulisher
Nov 09, 2024

Royalty Pharma Stock: Massive Opportunity Ahead (NASDAQ:RPRX) - Seeking Alpha

Nov 09, 2024
pulisher
Nov 08, 2024

Morgan Stanley's Strategic Reduction in Royalty Pharma PLC Holdi - GuruFocus.com

Nov 08, 2024
pulisher
Nov 07, 2024

Royalty Pharma plc (NASDAQ:RPRX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 07, 2024
pulisher
Nov 07, 2024

Royalty Pharma to Acquire Royalty Interest in Geron's RYTELO for $125 Million - The Manila Times

Nov 07, 2024
pulisher
Nov 07, 2024

Royalty Pharma plc (RPRX) to Acquire Royalty Interest in Geron’s (GERN) RYTELO for $125M - StreetInsider.com

Nov 07, 2024
pulisher
Nov 07, 2024

Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million - StockTitan

Nov 07, 2024
pulisher
Nov 07, 2024

Royalty Pharma plc (NASDAQ:RPRX) Shares Acquired by Robeco Institutional Asset Management B.V. - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Royalty Pharma PLC (RPRX) Q3 2024 Earnings Call Highlights: Strong Growth and Strategic Acquisitions - Investing.com Canada

Nov 07, 2024
pulisher
Nov 07, 2024

Royalty Pharma PLC (RPRX): A Strategic SWOT Insight - Yahoo Finance

Nov 07, 2024
pulisher
Nov 07, 2024

Royalty Pharma Reports Strong Q3 2024 Results - TipRanks

Nov 07, 2024
pulisher
Nov 06, 2024

Compared to Estimates, Royalty Pharma (RPRX) Q3 Earnings: A Look at Key Metrics - Yahoo Finance

Nov 06, 2024
pulisher
Nov 06, 2024

Earnings call: Royalty Pharma reports robust Q3 growth, raises guidance By Investing.com - Investing.com Nigeria

Nov 06, 2024
pulisher
Nov 06, 2024

Royalty Pharma reports robust Q3 growth, raises guidance By Investing.com - ழ தொலைக்காட்சி

Nov 06, 2024
pulisher
Nov 06, 2024

Earnings call: Royalty Pharma reports robust Q3 growth, raises guidance - Investing.com

Nov 06, 2024
pulisher
Nov 06, 2024

Royalty Pharma Reports Third Quarter 2024 Results - ForexTV.com

Nov 06, 2024
pulisher
Nov 06, 2024

Royalty Pharma plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 06, 2024
pulisher
Nov 06, 2024

Royalty Pharma Q3 Soars: 15% Revenue Growth, $1.2B Deployment Drives Guidance Boost | RPRX Stock News - StockTitan

Nov 06, 2024

Royalty Pharma Plc Stock (RPRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Royalty Pharma Plc Stock (RPRX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
RIGGS RORY B
Director
Jan 03 '24
Sale
27.79
199,098
5,532,276
55,801
RIGGS RORY B
Director
Jan 04 '24
Sale
27.55
35,702
983,504
20,099
Avara Management Ltd
10% Owner
Dec 29 '23
Sale
28.04
65,803
1,845,406
2,477,520
Avara Management Ltd
10% Owner
Dec 28 '23
Sale
28.20
209,863
5,918,934
2,543,323
Avara Management Ltd
10% Owner
Dec 27 '23
Sale
28.01
41,729
1,168,754
2,753,186
Avara Management Ltd
10% Owner
Dec 15 '23
Sale
28.01
10,229
286,499
2,794,915
Avara Management Ltd
10% Owner
Dec 14 '23
Sale
28.91
364,441
10,534,276
2,805,144
Avara Management Ltd
10% Owner
Dec 13 '23
Sale
28.95
307,935
8,916,012
3,169,585
$18.94
price down icon 1.35%
$75.45
price up icon 0.87%
$43.39
price up icon 3.19%
$378.13
price up icon 0.30%
$206.16
price up icon 7.31%
$120.72
price up icon 1.84%
Cap:     |  Volume (24h):